ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker

Company Developments - Abbott Laboratories has completed the world's first-in-human leadless left bundle branch area pacing (LBBAP) procedures, part of the Leadless CSP feasibility study, evaluating the safety and performance of the AVEIR CSP leadless pacemaker system [1][5] - The AVEIR leadless pacemaker is a key driver for Abbott's Cardiac Rhythm Management business, which is expected to strengthen following this development [2][4] - Abbott's AVEIR CSP leadless pacemaker system received Breakthrough Device Designation from the FDA, expediting the review process for innovative technologies [5] Financial Performance - Abbott has a market capitalization of $195.33 billion and an earnings yield of 4.1$625.5 million in 2023 and is projected to grow at a compound annual growth rate of 15.5% through 2030, driven by an aging population and increasing incidence of cardiovascular diseases [6] - The integration of CSP procedures with leadless pacemaker technology is expected to provide unique benefits over traditional pacemakers, such as eliminating the need for cardiac leads and reducing long-term complications [4] Stock Performance - Following the announcement of the leadless pacing procedures, Abbott's shares increased by 0.6%, closing at $113.29 [2] - Over the past six months, Abbott's shares have risen by 8.9%, outperforming the industry growth of 7.9% [9]